Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

About this update from Zealand Pharma A/s

[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hruCjDK29WWlg5.YGk148A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OQ--/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Eric Rojas","length":10,"tagName":"p"},{"type":"image","alt":"VP, Head of Investor Relations","displaySize":"","headline":null,"caption":"VP, Head of Investor Relations","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1996,"height":2048,"url":"https://media.zenfs.com/en/globenewswire.com/6bdad6681dc57f9572bba738d794a5e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T8upcSOnr_tNbEV0Uxr.0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk4NQ--/https://media.zenfs.com/en/globenewswire.com/6bdad6681dc57f9572bba738d794a5e3","width":960,"height":985},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/If6GVQuUnYijuyYfUsYvcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yNDYy/https://media.zenfs.com/en/globenewswire.com/6bdad6681dc57f9572bba738d794a5e3","width":1200,"height":1231}}},{"type":"text","content":"Press release – No. 7 / 2026 ","length":29,"tagName":"p"},{"type":"text","content":"Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations ","length":83,"tagName":"p"},{"type":"text","content":"Bringing significant experience from Vertex Pharmaceuticals and Shire ","length":69,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, Chief Financial Officer, and will be based in Massachusetts, U.S.","length":406,"tagName":"p"},{"type":"text","content":"Eric brings more than two decades of experience in investor relations and finance, having supported both US-listed and European-listed companies across biotech and pharma. He has held senior rol...

More updates from Zealand Pharma A/s